FDA Approved Weight Loss Drugs: Complete 2026 Guide

Summary: The FDA has approved nine weight loss medicines for chronic use. GLP-1 and GIP drugs like Zepbound and Wegovy now produce 15 to 22 percent average weight loss, two to four times what older pills like Contrave, Qsymia, and orlistat deliver.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: as of May 2026, the FDA has approved nine prescription drugs for chronic weight management. The newest GLP-1 and dual GIP/GLP-1 medicines (Wegovy, Zepbound, Wegovy HD, Foundayo) produce 12 to 22 percent average weight loss in trials ^[4][5]. The older drugs (Saxenda, Contrave, Qsymia, orlistat, Plenity) sit at 3 to 11 percent. That gap is the entire story of obesity medicine in the 2020s.

Below is each drug, the year the FDA approved it, how it works, the average weight loss in the pivotal trial, the side effects that matter, the typical cash price, and who it is actually for.

The full list, ranked by trial weight loss

The list above excludes setmelanotide (Imcivree), which is FDA approved only for four rare genetic obesity disorders confirmed by genetic testing ^[3], and it excludes Mounjaro, Ozempic, and Rybelsus, which contain tirzepatide or semaglutide but are FDA approved for type 2 diabetes rather than weight loss. Those diabetes-only versions cause significant weight loss in trials, which is why off-label prescribing happens, but they are not weight loss indications on the FDA label.

The GLP-1 and GIP class: 15 to 22 percent weight loss

This is what changed obesity medicine. Before 2021, no FDA-approved weight loss drug had ever produced 15 percent average weight loss in a pivotal trial. Now four drugs do.

Wegovy (semaglutide 2.4 mg), approved June 2021

Novo Nordisk's Wegovy was the first GLP-1 receptor agonist approved specifically for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition ^[1]. The FDA later expanded the indication to adolescents 12 and older, then to cardiovascular risk reduction in people with established heart disease, and most recently to metabolic dysfunction-associated steatohepatitis (MASH) ^[4].

Mechanism. Semaglutide is a GLP-1 receptor agonist. It mimics the gut hormone glucagon-like peptide-1, which slows gastric emptying, suppresses appetite at the level of the hypothalamus, and amplifies meal-stimulated insulin release. People feel full faster and stay full longer.

Average weight loss. In the STEP 1 trial that supported approval, adults on Wegovy lost 14.9 percent of body weight at 68 weeks versus 2.4 percent on placebo ^[1]. 83.5 percent of Wegovy patients lost at least 5 percent of body weight, the threshold most clinicians consider clinically meaningful.

Side effects. Nausea (44 percent), diarrhea (30 percent), vomiting (24 percent), constipation (24 percent). Most are mild to moderate and concentrated in the titration weeks. The boxed warning covers thyroid C-cell tumors based on rodent data; the label contraindicates use if you or a first-degree relative has medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 ^[1].

Cost. List price runs around 1,350 dollars per month cash. Novo's direct-to-patient program (NovoCare) sells Wegovy for around 499 dollars per month to people without insurance coverage. Insurance coverage for weight loss indications remains spotty; Medicare Part D does not cover Wegovy for obesity but will cover it for the cardiovascular risk reduction indication.

Who it is for. Adults and adolescents 12+ with obesity, or overweight plus a weight-related comorbidity. Particularly attractive for patients with established cardiovascular disease given the FDA cardiovascular indication.

Zepbound (tirzepatide), approved November 2023

Eli Lilly's Zepbound is the same molecule as Mounjaro, packaged and labeled for chronic weight management instead of diabetes. It is the only dual GIP/GLP-1 receptor agonist on the market and currently the most effective weight loss drug the FDA has approved ^[2].

Mechanism. Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. The dual mechanism produces larger appetite suppression and larger weight loss than GLP-1 alone in head-to-head data ^[4].

Average weight loss. In SURMOUNT-1, adults on the maximum 15 mg dose lost 20.9 percent of body weight at 72 weeks; the 10 mg dose produced 19.5 percent and the 5 mg dose 15.0 percent ^[5]. In SURMOUNT-5, the first direct head-to-head against semaglutide 2.4 mg, Zepbound delivered 20.2 percent versus 13.7 percent for semaglutide over 72 weeks. That is a 47 percent greater relative weight loss ^[4].

Side effects. Same profile as semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain. Same thyroid C-cell tumor boxed warning. Same contraindication for medullary thyroid cancer and MEN 2 history ^[2].

Cost. List price around 1,060 dollars per month for the pens. Lilly sells single-dose vials direct to cash-pay patients through LillyDirect at 349 to 499 dollars per month depending on the dose.

Who it is for. Adults with obesity or overweight plus a weight-related condition. In December 2024, the FDA also approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, making it the first prescription drug ever approved for OSA ^[4].

Wegovy HD (semaglutide 7.2 mg), approved March 2026

In March 2026 the FDA approved a high-dose version of injectable Wegovy at 7.2 mg weekly. Prior to this approval the highest approved dose had been 2.4 mg ^[4]. Wegovy HD is intended for adults who have tolerated the 2.4 mg dose for at least four weeks and need additional weight loss.

Average weight loss. In the STEP UP trial of 1,407 adults with obesity, Wegovy HD produced about 21 percent body weight loss at 72 weeks among those who stayed on therapy. About 31 percent of patients hit the 25 percent weight loss threshold, double the 15 percent rate seen with the 2.4 mg dose ^[4]. This is the first semaglutide regimen with weight loss in the same neighborhood as tirzepatide.

Side effects and cost. The safety profile mirrors standard Wegovy with slightly higher GI rates at the larger dose. Cash price is comparable to standard Wegovy.

Foundayo (orforglipron), approved April 2026

Eli Lilly's Foundayo is the first non-peptide oral GLP-1 receptor agonist approved for weight loss ^[4]. Unlike Wegovy oral tablets, which require fasted administration and water restrictions, Foundayo can be taken any time of day with or without food. That is a real adherence advantage.

Average weight loss. In the ATTAIN-1 phase 3 program, top doses produced 11 to 12 percent weight loss at 72 weeks ^[4]. That is meaningfully less than injectable Zepbound or Wegovy HD but meaningfully more than older oral options like Qsymia or Contrave. There are no head-to-head trials against injectable GLP-1s yet, so cross-trial comparisons should be read with caution.

Side effects. GI effects (nausea, diarrhea, vomiting) at rates similar to other GLP-1 agonists. No boxed warning for thyroid C-cell tumors in the rodent data published to date, though Foundayo is contraindicated in patients with personal or family history of medullary thyroid cancer or MEN 2 as a class precaution.

Cost. Lilly priced Foundayo competitively with injectable GLP-1s at launch; cash prices were running 399 to 499 dollars per month in early 2026.

Who it is for. Adults with obesity or overweight plus a comorbidity who want an oral option, who cannot tolerate injections, or whose insurance favors oral formulations.

Saxenda (liraglutide), approved December 2014

Novo Nordisk's Saxenda was the first GLP-1 receptor agonist FDA-approved for weight loss ^[3]. It is dosed daily by subcutaneous injection at 3.0 mg, three times the dose of the diabetes formulation Victoza.

Average weight loss. In the SCALE trial of 3,731 adults, Saxenda produced 8.0 percent body weight loss at 56 weeks versus 2.6 percent on placebo. 62 percent of patients lost at least 5 percent of body weight versus 34 percent on placebo ^[4].

Side effects. Same GLP-1 profile (nausea, vomiting, diarrhea), same medullary thyroid carcinoma contraindication. Daily injection is the main drawback versus weekly semaglutide or tirzepatide.

Cost. List price around 1,350 dollars per month. A generic liraglutide was FDA-approved on December 23, 2024, but only for the type 2 diabetes indication (Victoza dosing); a generic for the Saxenda obesity dose is not yet on the market ^[4].

Who it is for. Adults and adolescents 12+ with obesity or overweight plus a comorbidity. Saxenda is approved for patients as young as 12 with a body weight above 60 kg, which makes it useful in adolescent obesity programs where Wegovy is not preferred for some reason.

The pre-2021 oral drugs: 5 to 11 percent weight loss

These drugs predate the GLP-1 era. They still work, the FDA still approves them, and they remain useful in patients who cannot or will not take injections, who do not tolerate GLP-1 side effects, or who cannot afford a 500-dollar-per-month medication.

Qsymia (phentermine-topiramate ER), approved July 2012

Vivus's Qsymia combines two old drugs: phentermine, a sympathomimetic appetite suppressant from the 1950s, and topiramate, an anticonvulsant. The combination produces more weight loss than either drug alone and at lower doses than either monotherapy, which reduces side effects ^[3].

Mechanism. Phentermine suppresses appetite through central noradrenergic activity. Topiramate's weight loss mechanism is not fully understood but probably involves appetite suppression and increased satiety.

Average weight loss. In the CONQUER trial, the top dose (15 mg phentermine / 92 mg topiramate ER) produced 9.8 percent weight loss at 56 weeks. The mid dose (7.5 mg / 46 mg) produced 7.8 percent.

Side effects. Paresthesias (tingling), dry mouth, constipation, taste alteration, insomnia. Topiramate can cause cognitive blunting at higher doses. The drug is contraindicated in glaucoma, hyperthyroidism, and within 14 days of MAOI use ^[3]. Topiramate is teratogenic; women of reproductive age need a pregnancy test before starting and monthly during treatment.

Cost. Brand cash price around 200 to 250 dollars per month. Approved for adults and adolescents 12+ ^[3].

Who it is for. Patients who want an oral option, who get migraines (topiramate is FDA-approved for migraine prevention separately), and who do not have cardiovascular contraindications to a sympathomimetic.

Contrave (naltrexone-bupropion ER), approved September 2014

Currax Pharmaceuticals (originally Orexigen) markets Contrave, a fixed-dose combination of bupropion (the antidepressant and smoking cessation drug) and naltrexone (the opioid antagonist used in alcohol use disorder) ^[3].

Mechanism. Bupropion stimulates POMC neurons in the hypothalamus, which release alpha-MSH and reduce appetite. Naltrexone blocks the negative feedback loop that normally shuts those POMC neurons down. The combination produces sustained appetite suppression that neither drug alone delivers.

Average weight loss. In the COR-I trial, patients on full-dose Contrave lost 6.1 percent of body weight at 56 weeks versus 1.3 percent on placebo. 48 percent achieved at least 5 percent weight loss versus 16 percent on placebo. Real-world weight loss is closer to 5 percent.

Side effects. Nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth. The boxed warning covers suicidal ideation (bupropion class effect in younger adults) and is contraindicated in uncontrolled hypertension, seizure disorders, eating disorders, chronic opioid use, and within 14 days of MAOIs ^[3].

Cost. Cash price around 100 to 150 dollars per month, often lower with manufacturer copay programs.

Who it is for. Adults who also struggle with depression, smoking cessation, or alcohol cravings, since one half of the combination addresses each. Not for adolescents.

Xenical and Alli (orlistat), approved 1999 / 2007 OTC

Orlistat is the oldest still-approved weight loss drug. Xenical at 120 mg three times daily is prescription; Alli at 60 mg three times daily has been over the counter since February 2007 ^[3].

Mechanism. Orlistat inhibits pancreatic and gastric lipase, blocking absorption of about 30 percent of dietary fat. The unabsorbed fat passes through the GI tract.

Average weight loss. In long-term trials, Xenical produced 5 to 10 percent body weight loss at one year versus 3 to 6 percent on placebo. OTC Alli at the lower dose produces roughly 3 to 5 percent additional weight loss versus diet alone.

Side effects. The side effects are the mechanism. Oily stools, fecal urgency, oily spotting, flatus with discharge, abdominal pain. Patients who eat low-fat meals avoid most of this; patients who do not are usually back off the drug within a month. Orlistat reduces absorption of fat-soluble vitamins (A, D, E, K) and beta-carotene; a daily multivitamin two hours apart from doses is standard ^[3].

Cost. Alli OTC runs 50 to 70 dollars for a starter pack. Xenical prescription is around 750 dollars per month brand or 100 dollars per month generic.

Who it is for. Adults and adolescents 12+ ^[3]. Best in patients with high baseline fat intake who can use the side effect threat as a behavioral nudge toward lower-fat eating.

Plenity (cellulose and citric acid hydrogel), approved April 2019

Plenity is technically an FDA-cleared device rather than a drug, but it sits on weight loss medication lists and is commonly prescribed. Gelesis (now Roman Sciences) markets it for adults with BMI 25 to 40.

Mechanism. Three capsules taken with 16 ounces of water 20 minutes before lunch and dinner. The capsules contain a hydrogel made from modified cellulose and citric acid that absorbs water in the stomach and small intestine, expanding to occupy about a quarter of stomach volume and triggering satiety signals. The hydrogel passes through the GI tract and is excreted.

Average weight loss. In the GLOW trial, Plenity produced 6.4 percent body weight loss at 24 weeks versus 4.4 percent on placebo. 59 percent of patients achieved at least 5 percent weight loss versus 42 percent on placebo. The placebo effect is unusually large because the comparator is also "drink 16 ounces of water before meals."

Side effects. GI: bloating, fullness, abdominal pain, diarrhea, flatulence. Generally well tolerated. Not a controlled substance, no boxed warning, no significant drug interactions.

Cost. Cash price around 100 dollars per month through Roman or other telehealth platforms. Often the cheapest option.

Who it is for. Adults with BMI 25 to 40 who want a non-systemic, low-side-effect option and who can tolerate the strict pre-meal water requirement.

Older drugs the FDA approved but most clinicians no longer prefer

The FDA has also withdrawn several weight loss drugs that earlier rounds of clinical experience showed were unsafe: sibutramine (Meridia, withdrawn 2010 for cardiovascular events), rimonabant (never approved in the US for psychiatric risk), lorcaserin (Belviq, withdrawn 2020 for cancer risk), and the fenfluramine combinations of the 1990s. Modern weight loss pharmacology has a long tail of failed approvals behind it. That history is one reason clinicians evaluate new drugs cautiously and one reason the FDA requires the multi-year cardiovascular outcomes trials now standard for this class.

How the modern era compares to the older era

Run the numbers and the gap is stark.

A patient who needs to lose 50 pounds is going to lose roughly 50 pounds on Zepbound, 35 pounds on Wegovy, 22 pounds on Qsymia, and 12 pounds on Contrave at average response. The decision between drugs in the 2020s is rarely "what is most effective" anymore. It is "what is most effective that the patient can tolerate, afford, and stick with."

Side effects, by class

For all GLP-1 and GIP/GLP-1 drugs, the FDA labels also note a class precaution for pulmonary aspiration during anesthesia. Tell every surgical or procedural team that you are on a GLP-1, even if you fasted as instructed ^[4].

Cost in 2026

Cash prices change constantly. Both Novo and Lilly cut direct-to-patient prices repeatedly in 2024 and 2025, and Foundayo entered the market at a deliberately disruptive price point ^[4]. Insurance coverage for any weight loss medication remains the harder battle. Medicare does not cover any of these drugs for the obesity indication; commercial coverage varies wildly by employer. Patients who qualify for the cardiovascular indication on Wegovy or the MASH indication may obtain coverage that would otherwise be denied.

Who is each drug actually for

• GLP-1 / GIP injection (Zepbound, Wegovy, Wegovy HD, Saxenda): Adults with obesity (BMI 30+) or overweight (BMI 27+) with a comorbidity. First-line for patients who can tolerate injections and afford them. Particularly strong choice for patients with type 2 diabetes (since Mounjaro and Ozempic share the active ingredients), with established cardiovascular disease (Wegovy CV indication), with OSA (Zepbound OSA indication), or with MASH (Wegovy MASH indication).
• GLP-1 oral (Foundayo, Wegovy tablets): Patients who want a daily pill instead of a weekly injection. Foundayo's any-time dosing wins for adherence; Wegovy tablets require fasted morning dosing with limited water.
• Phentermine-topiramate (Qsymia): Adults and adolescents 12+ who want an oral, prefer a stimulant mechanism, and may benefit from topiramate's separate efficacy in migraine. Avoid in cardiovascular disease or pregnancy.
• Naltrexone-bupropion (Contrave): Adults who could use the bupropion side benefits (depression, smoking cessation). Patients with hedonic eating (food cravings rather than hunger) sometimes respond particularly well. Not for opioid users or seizure history.
• Orlistat (Xenical / Alli): Patients with high baseline dietary fat who want a non-systemic mechanism. Side effects function as behavioral training.
• Plenity: Adults with BMI 25 to 40 who want the lowest side-effect profile and the lowest cost, who do not need 15 percent body weight loss to hit their goal.

Things weight loss drugs do not do

The drugs also do not replace evaluation of underlying drivers of weight gain. Hypothyroidism, Cushing's syndrome, PCOS, sleep apnea, depression, binge eating disorder, and weight-gain-promoting medications (some antipsychotics, some antidepressants, insulin, corticosteroids) all need to be ruled out or addressed before or alongside drug therapy. A good obesity workup is a good general medicine workup.

Common questions

What is the safest FDA approved weight loss pill?

Orlistat (Xenical, Alli) has the longest safety record (approved 1999) and no systemic mechanism, but its GI effects are unpleasant. Plenity has the cleanest side-effect profile of any approved option. For most patients, the GLP-1 agonists have a favorable risk-benefit ratio at the doses studied.

Which FDA approved weight loss drug works fastest?

Tirzepatide (Zepbound) shows the steepest weight loss curve in trials, with measurable loss in the first 4 weeks and full effect by 36 to 72 weeks. Pills like Qsymia and Contrave show benefit by week 12, which is also when the FDA recommends stopping if you have not lost at least 5 percent of starting weight.

How does phentermine work for weight loss?

Phentermine is a sympathomimetic that triggers norepinephrine release in the hypothalamus, suppressing appetite. As monotherapy it is FDA-approved only for short-term use (12 weeks or less). The chronic-use approved version is Qsymia, where phentermine is combined with topiramate at lower doses.

Is naltrexone a weight loss pill on its own?

No. Naltrexone alone is FDA-approved for opioid and alcohol use disorder, not weight loss. The naltrexone weight loss product is Contrave, where naltrexone is combined with bupropion. The combination works; naltrexone alone produces minimal weight loss.

How much weight can you lose on Contrave in one month?

Roughly 1 to 2 percent of starting body weight in the first month, given the slow titration schedule (one tablet daily for week 1, escalating to two tablets twice daily by week 4). Most patients see meaningful weight loss by week 12.

Are weight loss pills good or bad?

They are tools. Pills approved by the FDA in the last 30 years have undergone trials showing meaningful weight loss and acceptable safety profiles for the labeled population. Withdrawn drugs (fenfluramine, sibutramine, lorcaserin) prove that not every weight loss drug stays on the market, which is the case for any drug class.

Do weight loss pills that work fast exist?

"Fast" in weight loss pharmacology means 5 percent body weight loss in 12 weeks, which is the FDA's threshold for continuing therapy. Real fast weight loss (more than 1 to 2 percent of body weight per week) is generally unsafe and not what any approved drug does.

What is the best weight loss medication for someone over 50?

The GLP-1 and GIP/GLP-1 agonists have been studied in adults up to age 75 with no upper age cutoff in the FDA label. Older adults need closer monitoring for dehydration if GI side effects appear and for any change in kidney function during titration. Cardiovascular indication on Wegovy is particularly valuable in this age group.

Can I take an FDA approved weight loss drug with Ozempic?

No. Ozempic is semaglutide; Wegovy is also semaglutide. Stacking two GLP-1 agonists is not safe and not approved. If you are on Ozempic for diabetes and want weight loss, your prescriber can switch you to Wegovy at the equivalent dose or change classes.

Will insurance cover any of these drugs?

Commercial insurance coverage for weight loss is improving but inconsistent. Medicare Part D does not cover weight loss drugs for the obesity indication. It will cover Wegovy for the cardiovascular risk reduction indication in eligible patients, Zepbound for sleep apnea, and Wegovy for MASH. Cash-pay programs from Novo and Lilly bring monthly prices into the 350 to 500 dollar range for the major GLP-1s.

What the list looks like in 12 months

The FDA's weight loss drug pipeline is the busiest it has been in 60 years. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist from Lilly, produced 24 percent weight loss in phase 2 and is in phase 3 trials with an expected approval window in 2026 to 2027. CagriSema (a semaglutide and cagrilintide combination from Novo) has phase 3 data and a regulatory filing in progress. Several other dual and triple agonists from smaller biotech are mid-clinical. The pre-2021 list of weight loss drugs sat untouched for years; the 2026 list is already different from the 2025 list, and the 2027 list will be different again.

For now, the FDA-approved set above is the legal toolkit. Pick the drug that fits the patient, dose it correctly, monitor for side effects and 12-week response, and continue indefinitely if it works. That is the modern playbook.